Gilead Sciences (NQ: GILD )

73.78 -0.56 (-0.75%)

Streaming Delayed Price Updated: 4:00 PM EDT, Aug 16, 2024 Add to My Watchlist

Price and Volume

Volume	5,148,100
Open	73.94
Bid (Size)	73.50 (2)
Ask (Size)	73.95 (2)
Prev. Close	74.34
Today's Range	72.89 - 74.24
52wk Range	62.07 - 87.86
Shares Outstanding	1,253,809,440
Dividend Yield	4.07%

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

Gilead's Ongoing Battle Against Counterfeit HIV Medications Persists With New Lawsuit, Seizes $750K In Fake Drugs

August 16, 2024

Gilead Sciences exposes a major counterfeiting ring led by Peter Khaim, involving tampered HIV medications resold from New York pharmacies. The company seized over $750K in fake drugs, intensifying its...

Via Benzinga

FDA Approves Gilead's Seladelpar For Inflammatory Liver Disease, Acquired Via $4B CymaBay Deal

August 15, 2024

FDA grants accelerated approval to Gilead's Livdelzi (seladelpar) for primary biliary cholangitis, offering new treatment options for patients with inadequate response to standard therapy. Continued...

Via Benzinga

Performance

YTD	-11.36%	-11.36%
1 Month	+0.65%	+0.65%
3 Month	+8.95%	+8.95%
6 Month	+3.07%	+3.07%
1 Year	-3.56%	-3.56%

More News

Expert Outlook: Gilead Sciences Through The Eyes Of 8 Analysts

August 15, 2024

Via Benzinga

Gilead’s Livdelzi (Seladelpar) Granted Accelerated Approval for Primary Biliary Cholangitis by U.S. FDA

August 14, 2024

From Gilead Sciences, Inc.

Via Business Wire

7 Defensive Stocks to Buy as Investors Seek Shelter

August 14, 2024

Via InvestorPlace

Gilead Eyes A Breakout After Second-Quarter Sales, Earnings Beat

August 08, 2024

Via Investor's Business Daily

$1000 Invested In Gilead Sciences 20 Years Ago Would Be Worth This Much Today

August 06, 2024

Via Benzinga

3 Stocks Retirees Should Absolutely Love

August 10, 2024

Via The Motley Fool

Analysts Cite Improved Investor Sentiment For Gilead, But Warn of Limited Growth at Current Stock Levels

August 09, 2024

Via Benzinga

Wall Street Momentum Stalls After Thursday's Rally, Palantir Jumps To 3-Year Highs, Bonds Rally: What's Driving Markets Friday?

August 09, 2024

Via Benzinga

Gilead Sciences's Options Frenzy: What You Need to Know

July 30, 2024

Via Benzinga

$100 Invested In Gilead Sciences 20 Years Ago Would Be Worth This Much Today

July 29, 2024

Via Benzinga

Gilead Sciences (GILD) Q2 2024 Earnings Call Transcript

August 08, 2024

Via The Motley Fool

GILD Stock Earnings: Gilead Sciences Beats EPS, Beats Revenue for Q2 2024

August 08, 2024

Via InvestorPlace

Gilead Sciences Announces Second Quarter 2024 Financial Results

August 08, 2024

From Gilead Sciences, Inc.

Via Business Wire

Wall Street Set For Uneventful Start Ahead Of Jobless Claim Data, VIX Rises: Strategist Says Market May Remain Vulnerable Until...

August 08, 2024

Via Benzinga

Wall Street Rallies As Economic Concerns Recede, Tech Flexes Its Muscles, Semiconductors Soar: What's Driving Markets Thursday?

August 08, 2024

Via Benzinga

Four Stocks To Watch This Week - Monday, August 5

August 05, 2024

Via Talk Markets

2 Unstoppable Dividend Stocks to Buy if There's a Stock Market Sell-Off

August 03, 2024

Via The Motley Fool

Q3’s Rising Stars: 3 Nasdaq Stocks for Your Must-Watch List

August 02, 2024

Via InvestorPlace

Benzinga's 'Stock Whisper' Index: 5 Stocks Investors Secretly Monitor But Don't Talk About Yet

August 02, 2024

Via Benzinga

The Top 3 Biotech Stocks to Buy Now Summer 2024

July 31, 2024

Via InvestorPlace

Kazia Therapeutics Stock: Is KZIA a Buyout Candidate in the Making?

July 31, 2024

Via InvestorPlace

Wall Street's Most Accurate Analysts Say Hold These 3 Health Care Stocks With Over 3% Dividend Yields

July 29, 2024

Via Benzinga

10 Health Care Stocks Whale Activity In Today's Session

July 26, 2024

Via Benzinga

Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.